Sansure Biotech Inc.
Simbols: 688289.SS
SHH
20.62
CNYTirgus cena šodien
31.0215
P/E koeficients
0.0048
PEG koeficients
11.83B
MRK Cap
- 0.03%
DIV ienesīgums
Sansure Biotech Inc. (688289-SS) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 0 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 0 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 0 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 0 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 0 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 0 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 0 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 0 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 0 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 0 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 0 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 0 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 0 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 0 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 0 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 0 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 0 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | 0 | -4138 | -3184.7 | -2621.3 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 0 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | 0 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 0 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 0 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 0 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | 0 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | 0 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | 0 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 0 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | 0 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | 0 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | 0 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | 0 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 0 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 0 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 0 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 0 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | 0 | 2000.1 | 1504.2 | 2533.6 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 0 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 0 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | 0 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 0 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 0 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 0 | 363.7 | 1936.8 | 2242.7 |
Biežāk uzdotie jautājumi
Kas ir Sansure Biotech Inc. (688289.SS) kopējie aktīvi?
Sansure Biotech Inc. (688289.SS) kopējie aktīvi ir 8454204974.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.729.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.496.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.321.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.334.
Kāda ir Sansure Biotech Inc. (688289.SS) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 363721131.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 95444005.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 638676546.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.